Related-Party Transactions	9 Months Ended
	Sep. 30, 2023
Related Party Transactions [Abstract]
Related-Party Transactions	Related-Party TransactionsThe Company has outstanding licensing and scientific research agreements with Penn, a significant shareholder (Note 5). The Company recognized $0.3 million and $1.0 million of research and development expenses for the three months ended September 30, 2023 and 2022, respectively, related to the Penn License Agreement. The Company recognized $0.6 million and $1.4 million of research and development expenses for the nine months ended September 30, 2023 and 2022, respectively, related to the Penn License Agreement.The Company has a collaboration and license agreement with Moderna, a significant shareholder (Note 10).